Skin Diseases, Genetic  >>  mapracorat (BOL-303242-X)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mapracorat (BOL-303242-X) / Bayer
NCT00944632: Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis

Completed
2
64
RoW
ZK 245186, Placebo (vehicle ointment)
Bayer
Atopic Dermatitis
09/10
09/10
NCT01228513: Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

Completed
2
263
Japan, US
ZK245186, Mapracorat (BAY86-5319), Placebo (vehicle without active ingredient)
Bayer
Atopic Dermatitis
07/11
04/12
NCT01359787 / 2010-024279-14: Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)

Completed
2
197
Europe
Mapracorat, Vehicle without active
Bayer
Atopic Dermatitis, Eczema
09/11
09/11
NCT01407510: HPA Axis Study in Japanese Adults

Completed
2
12
Japan
Mapracorat
Bayer
Atopic Dermatitis, Eczema
09/11
04/12
NCT01408511: HPA Axis Study in Adults

Completed
2
23
RoW
Mapracorat
Bayer
Atopic Dermatitis, Eczema
12/11
12/11

Download Options